Introduction
Allogeneic stem cell transplantation (alloSCT) is successfully applied in the treatment of patients with hematological malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Treatment of relapsed leukemia after alloSCT with donor lymphocyte infusion (DLI) can induce longlasting complete remissions. T-cells recognizing minor histocompatibility antigens (mHags) on recipient hematopoietic cells are considered to play an important role in the anti-leukemic effect observed after DLI, as demonstrated by the detection of mHagspecific donor T-cells in patients responding to DLI. 1, 2 Complete remissions after DLI have been achieved in 80-90% of patients with CML in chronic phase, but only in 10-30% of patients with relapsed AML and ALL. 3, 4 Patients not responding to DLI may lack the in vivo environment for an efficient induction of mHag-specific T-cell responses.
This may be bypassed by the in-vitro generation of mHag-specific T-cells that can be adoptively transferred to patients with relapsed leukemia after transplantation. In a previous phase I/II feasibility study we treated patients with relapsed leukemia with in vitro generated leukemia-reactive T-cells. In some patients a clinical effect was observed, demonstrating a potential efficacy of the adoptive transfer of in vitro generated leukemia-reactive T-cells. 5, 6 The adoptive transfer of mHag-specific T cell clones has been described by Warren et al 7 , providing evidence that transferred Tcells can exert anti-leukemic activity, although no long term persistence of the T cell clones was observed and all patients eventually relapsed. Since we previously illustrated that T-cells specific for the mHag HA-1 appeared to significantly contribute to clinical responses after DLI and it has been shown that mHag-specific CD8+ T cells can have anti-leukemic activity, 1, 7 we investigated the feasibility of the adoptive transfer of in vitro induced HA-1-specific CD8 positive T-cell lines in patients with relapsed leukemia after alloSCT.
Design and Methods

Generation of dendritic cells
Clinical grade immature dendritic cells (DC) were generated by (1) culturing CD34 positive cells derived from the donor peripheral blood stem cell graft with 100 ng/ml GM-SCF (Novartis, Basel, Switzerland), 20 ng/ml human stem cell factor (huSCF) (a kind gift of Amgen, Thousand Oaks, CA), and 2 ng/ml TNFα (Cellgro 1006, Cellgenix, Freiburg, Germany) and from day 4 500 IU/m IL-4 (kindly provided by Schering Plough, Innishammon, Cork, Ireland), or by (2) culturing CD14 positive cells derived from donor peripheral blood with 100 ng/ml GM-CSF, 500 IU/ml IL-4 and 100 IU/ml IFNα-2a
(Roferon-A, Roche, Basel, Switzerland) for 5 days. Immature CD34-or CD14-derived DC were maturated using DKTP (diphtheria, whooping cough, tetanus and polio) vaccine, diluted 1:1000 (RIVM, Bilthoven, The Netherlands).
Generation of HA-1-specific T-cell lines
After informed consent, HA-1-specific donor T-cell lines were generated by culturing 
Results and Discussion
A total of nine HA-1-specific CD8 + T cell lines were generated after stimulation with HA- This may indicate survival of the infused T-cell line at low frequencies, although, very low frequencies of HA-1 specific CD8+ T-cells could also be detected prior to infusion of the HA-1-specific CD8+ T cell line. For patient NMJ peripheral blood samples and bone marrow samples up to 2 weeks after infusion were available, and for patient KHP peripheral blood samples up to 3 weeks (KHP) after infusion were available. No HA-1-specific CD8+ T-cells could be detected in these samples from both patients.
In this study, we have shown that in vitro generation of clinical grade HA-1-specific Tcell lines is feasible. However, at least four weeks and in most cases five weeks of culture were necessary to obtain HA-1-specific T cell lines containing significant numbers of HA-1-specific T cells. This culture period was too long, and obtained cell numbers may have been to low, for patients with rapidly growing leukemia (patient KHP and NMJ). In patients with persistent CMV of EBV reactivation after transplantation, infusion of low numbers of antigen specific T cells has resulted in in vivo expansion and sustained immune responses 13, 14 . However, our culture protocol led to the infusion of T-cell lines with an effector memory phenotype that might have had a limited capacity to survive and expand in vivo. 7, 12 In addition, the high dose of IL-2 used during the culture period might have led to IL-2 dependency of the HA-1-specific T-cells, which also can have contributed to their lack of in vivo persistence. 11, 12 Additionally, the lack of HA-1 specific CD4+ T cells may have contributed to the lack of in vivo persistence, since it has been shown that virus-specific CD8+ T-cells may show better persistence in the presence of virus-specific CD4+ T-cells. 15 The relapsed tumor cells may also have had a reduced susceptibility to killing by the antigen specific T cells, e.g. by downregulation of HLA molecules, leading to impaired presentation of HA-1 on the tumor cells. However, since the leukemic blasts were susceptible to lysis by HA-1 specific CD8+ T cells in our in vitro 51 Cr-relases assay (table 1) , we do not expect that escape of the tumor cells did significantly contributed to the lack of antileukemic reactivity of the HA-1 specific T cells.
Three patients were treated with HA-1-specific T-cell lines. After infusion no toxicity was observed, showing that administration of these T-cell lines was safe. Although in one patient during a period of stable disease HA-1-specific T-cells could be detected in the peripheral blood and bone marrow, no clear clinical response occurred in these patients. In the study of Warren et al, where high numbers of mHag-specific T cell clones were infused in patients with relapsed leukemia, transient remissions were observed after adoptive transfer, which might be related to the difference in cell numbers infused. 7 However, also in their study no durable in vivo persistence of the mHag-specific T-cells could be demonstrated.
To improve the anti-leukemic effect of mHag-specific T-cell lines, a strategy has to be developed for the early isolation of mHag-specific CD4+ and CD8+ T-cells. 16 Alternatively, TCR gene transfer may also be an attractive strategy for rapid in vitro generation of high-affinity mHag-specific T-cells. 17, 18 The in vitro culture period should probably be limited, and more physiological culture conditions are necessary to enhance the in vivo potential of the mHag-specific T-cells. 12 This may result in a better anti-leukemic effect and in the development of a population of central memory type Tcells, which may be necessary for the long term control of the leukemia.
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